Abstract Postoperative radiotherapy is an important part of the comprehensive treatment for breast cancer. The quality of radiotherapy is crucial for both the long‐term prognosis and the quality of life of patients with breast cancer. The guideline is established to provide uniformed criteria, aiming to improve the capacity of breast cancer adjuvant radiotherapy in China. The guideline covers the whole process of radiotherapy, including patient selection, simulation, target and organ at risk (OAR) delineation, dose schemes, OAR dose limitation as well as treatment planning. Based on this guideline, each institution could develop personalized standard operating procedures according to its equipment and patient‐specific requirements.
Corresponding Authors:
Li Ye‐Xiong, Department of Radiation Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China, Email: yexiong12@163.com
Cite this article:
National Cancer Center / National Cancer Quality Control Center. Guideline of target delineation and treatment planning of adjuvant radiotherapy for breast cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(10): 863-878.
National Cancer Center / National Cancer Quality Control Center. Guideline of target delineation and treatment planning of adjuvant radiotherapy for breast cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(10): 863-878.
[1] NCCN. Guidelines of breast cancer. Version1[S], 2021. [2] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志, 2019, 29(8): 609‐680. DOI: 10.19401/j. cnki. 1007‐3639. 2019.08.009. Breast Cancer Committee of China Anti-cancer Association. Guidelines and Specifications for Diagnosis and Treatment of Breast Cancer of China Anti-cancer Association (2019 Edition)[J]. China Cancer J,2019, 29(8): 609‐680. DOI: 10.19401/j. cnki. 1007‐3639. 2019.08.009. [3] Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast‐conserving surgery on 10‐year recurrence and 15‐year breast cancer death: meta‐analysis of individual patient data for 10,801 women in 17 randomised trials[J]. Lancet, 2011, 378(9804):1707‐1716. DOI: 10.1016/S0140‐6736(11)61629‐2. [4] Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long‐term follow‐up of CALGB9343[J]. J Clin Oncol,2013, 31(19):2382‐2387. DOI: 10.1200/JCO. 2012.45.2615. [5] Kunkler IH, Williams LJ, Jack WJ, et al. Breast‐conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial[J]. Lancet Oncol, 2015, 16(3):266‐273. DOI: 10.1016/S1470‐2045(14)71221‐5. [6] McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10‐year recurrence and 20‐year breast cancer mortality: meta‐analysis of individual patient data for8135 women in 22 randomised trials[J]. Lancet, 2014, 383(9935):2127‐2135. DOI: 10.1016/S0140‐6736(14)60488‐8. [7] Kaššák F, Rossier C, Picardi C, et al. Postmastectomy radiotherapy in T1‐2 patients with one to three positive lymph nodes ‐ Past, present and future[J]. Breast, 2019, 48:73‐81. DOI: 10.1016/j. breast. 2019.09.008. [8] Kim SI, Park S, Park HS, et al. Comparison of treatment outcome between breast‐conservation surgery with radiation and total mastectomy without radiation in patients with one to three positive axillary lymph nodes[J]. Int J Radiat Oncol Biol Phys, 2011, 80(5):1446‐1452. DOI: 10.1016/j. ijrobp. 2010.04.051. [9] Kim SW, Chun M, Han S, et al.Comparison of treatment outcomes between breast conserving surgery followed by radiotherapy and mastectomy alone in patients with T1‐2 stage and 1‐3 axillary lymph nodes in the era of modern adjuvant systemic treatments[J]. PLoS One, 2016, 11(9):e0163748. DOI: 10.1371/journal. pone. 0163748. [10] Velikova G, Williams LJ, Willis S, et al. Quality of life after postmastectomy radiotherapy in patients with intermediate‐risk breast cancer (SUPREMO): 2‐year follow‐up results of a randomised controlled trial[J]. Lancet Oncol, 2018, 19(11):1516‐1529. DOI: 10.1016/S1470‐2045(18)30515‐1. [11] Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local‐regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation[J]. J Clin Oncol, 2002, 20(1):17‐23. DOI: 10.1200/JCO. 2002.20.1.17. [12] Garg AK, Strom EA, McNeese MD, et al. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 59(1):138‐145. DOI: 10.1016/j. ijrobp. 2003.10.037. [13] McGuire SE, Gonzalez‐Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy[J]. Int J Radiat Oncol Biol Phys, 2007, 68(4):1004‐1009. DOI: 10.1016/j. ijrobp. 2007.01.023. [14] Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B‐18 and B‐27[J]. J Clin Oncol, 2012, 30(32):3960‐3966. DOI: 10.1200/JCO. 2011.40.8369. [15] Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel‐node micrometastases (IBCSG 23‐01): 10‐year follow‐up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1385‐1393. DOI: 10.1016/S1470‐2045(18)30380‐2. [16] Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10‐year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (alliance) randomized clinical trial[J]. JAMA, 2017, 318(10):918‐926. DOI: 10.1001/jama. 2017.11470. [17] Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer[J]. Radiother Oncol, 2015, 114(1):3‐10. DOI: 10.1016/j. radonc. 2014.11.030. [18] White J, Tai A, Arthur DA, et al.Breast cancer atlas for radiation therapy planning: Consensus definitions by RTOG[EB/OL].[2021‐01‐15].https: //www. rtog. org/LinkClick. aspx? fileticket=SQhssxHu7Jg%3d&tabid=227. [19] Furet E, Peurien D, Fournier‐Bidoz N, et al. Plastic surgery for breast conservation therapy: how to define the volume of the tumor bed for the boost?[J]. Eur J Surg Oncol, 2014, 40(7):830‐834. DOI: 10.1016/j. ejso. 2014.03.009. [20] Huang W, Currey A, Chen X, et al. A comparison of lumpectomy cavity delineations between use of magnetic resonance imaging and computed tomography acquired with patient in prone position for radiation therapy planning of breast cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 94(4):832‐840. DOI: 10.1016/j. ijrobp. 2015.12.014. [21] Vargo JA, Beriwal S. RTOG chest wall contouring guidelines for post‐mastectomy radiation therapy: is it evidence‐based?[J]. Int J Radiat Oncol Biol Phys, 2015, 93(2):266‐267. DOI: 10.1016/j. ijrobp. 2015.03.001. [22] Steele KH, Macmillan RD, Ball GR, et al. Multicentre study of patient‐reported and clinical outcomes following immediate and delayed autologous breast reconstruction and radiotherapy (ABRAR study)[J]. J Plast Reconstr Aesthet Surg, 2018, 71(2):185‐193. DOI: 10.1016/j. bjps. 2017.10.030. [23] Kelley BP, Ahmed R, Kidwell KM, et al. A systematic review of morbidity associated with autologous breast reconstruction before and after exposure to radiotherapy: are current practices ideal?[J]. Ann Surg Oncol, 2014, 21(5):1732‐1738. DOI: 10.1245/s10434‐014‐3494‐z. [24] Cooke AL, Diaz‐Abele J, Hayakawa T, et al. Radiation therapy versus no radiation therapy to the neo‐breast following skin‐sparing mastectomy and immediate autologous free flap reconstruction for breast cancer: patient‐reported and surgical outcomes at 1 year‐a mastectomy reconstruction outcomes consortium (MROC) substudy[J]. Int J Radiat Oncol Biol Phys, 2017, 99(1):165‐172. DOI: 10.1016/j. ijrobp. 2017.05.001. [25] Kaidar‐Person O, Vrou Offersen B, Hol S, et al. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant‐based immediate reconstruction for early stage breast cancer[J]. Radiother Oncol, 2019, 137:159‐166. DOI: 10.1016/j. radonc. 2019.04.010. [26] Jethwa KR, Kahila MM, Hunt KN, et al. Delineation of internal mammary nodal target volumes in breast cancer radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2017, 97(4):762‐769. DOI: 10.1016/j. ijrobp. 2016.11.037. [27] Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer[J]. N Engl J Med, 2015, 373(4):317‐327. DOI: 10.1056/NEJMoa1415369. [28] Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early‐stage breast cancer[J]. N Engl J Med, 2015, 373(4):307‐316. DOI: 10.1056/NEJMoa1415340. [29] Thorsen LB, Offersen BV, Danø H, et al. DBCG‐IMN: A population‐based cohort study on the effect of internal mammary node irradiation in early node‐positive breast cancer[J]. J Clin Oncol, 2016, 34(4):314‐320. DOI: 10.1200/JCO. 2015.63.6456. [30] Khan AJ, Ahlawat S, Goyal S. Novel and highly compressed schedules for the treatment of breast cancer[J]. Semin Radiat Oncol, 2016, 26(1):45‐50. DOI: 10.1016/j. semradonc. 2015.09.001. [31] Wang SL, Fang H, Hu C, et al. Hypofractionated versus conventional fractionated radiotherapy after breast‐conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China[J]. J Clin Oncol, 2020, 38(31):3604‐3614. DOI: 10.1200/JCO. 20.01024. [32] Wang SL, Fang H, Song YW, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high‐risk breast cancer: a randomised, non‐inferiority, open‐label, phase 3 trial[J]. Lancet Oncol, 2019, 20(3):352‐360. DOI: 10.1016/S1470‐2045(18)30813‐1. [33] 田源,马攀,门阔,等.基于VMAT的乳腺癌保乳术后全乳混合调强技术的建立与评价[J].中华放射肿瘤学杂志, 2016, 25(7): 728‐732. DOI: 10.3760/cma. j. issn. 1004‐4221.2016. 07.014. Tian Y, Ma P, Men K, et al. Development and evaluation of whole breast irradiation with volumetric modulated arc therapy‐based hybrid intensity‐modulated radiotherapy after breast conserving surgery for breast cancer[J]. Chin J Radiat Oncol, 2016,25(7): 728‐732. DOI: 10.3760/cma.j.issn.1004‐4221. 2016.07.014. [34] 郭晨雷,徐英杰,戴建荣.乳腺癌容积调强弧形治疗的射野边界外放方法[J].中华放射肿瘤学杂志, 2018, 27(9): 845‐849. DOI: 10.3760/cma. j. issn. 1004‐4221.2018.09.012. Guo CL, Xu YJ, Dai JR. Margin expansion for treatment field of volumetric modulated arc therapy for breast cancer[J]. Chin J Radiat Oncol, 2018,27(9): 845‐849. DOI: 10.3760/cma.j.issn.1004‐4221.2018.09.012.
2022, Vol. 31 
